Screenen op suïciderisico bij diabetes: waarom artsen aarzelen, maar dat niet zouden moeten

Delen via:

Mary de Groot (Associate Professor of Medicine en directeur van het Diabetes Translational Research Center van Indiana University) legt in deze video het belang uit van screening op suïcidale gedachten bij mensen met diabetes, en gaat in op veelvoorkomende zorgen waardoor artsen misschien aarzelen om dit te doen (7:22).

  • Transcript

    So our topic is screening for suicide by health care providers. And thank you for the opportunity to speak to this topic today. I am a clinical psychologist and work closely with patients with diabetes in the context of an embedded health psychology service in adult endocrinology. And this is a topic that’s very important for all of us, whether we are mental health or behavioral health providers or endocrinologists or primary care providers, to have sensitivity to and to have a plan of action to address, because we know that both depression and suicidal ideation are much more prominent in our patient populations than we might initially imagine. So let’s talk a little bit about the nuts and bolts of screening. So one of the things we know is that screening for depression and suicidal ideation are a part of the standards of medical care for people with diabetes. This is built into the standards of care for the American Diabetes Association, and those same standards have been adopted internationally. So why would we possibly want to ask our patients about depression and suicide? That sounds like a really downer topic, doesn’t it? And in fact, as health care providers, perhaps not you as the listener here, but perhaps many of your colleagues, we all know colleagues who have a considerable amount of feelings about doing this kind of screening. We have fears that screening for feelings of depression or suicidal ideation may be beyond the scope of our practice. I may not feel trained to be able to ask those questions and know what to doing. We may make some assumptions that it doesn’t apply to the patient that’s sitting directly in front of us. And in many cases that might be true– that assumption might hold true. But there may be other cases in which we don’t actually know that the person that is sitting before us has been struggling with mood or struggling with suicidal ideation. And unless we ask, we won’t know. Although, that will still be there for them, whether we ask or not. And so asking those questions are very important so that we can get that on the table and be able to work with it. Sometimes, as health care providers, we have fears that asking open-ended questions might take up too much time in the clinical encounter. We all wrestle with our schedules. We wrestle with the amount of time– the limited amount of time– we have to work with our patients and particularly our patients with diabetes. And so asking questions like, how is your mood, or what would you like from your appointment today, or have you been feeling safe, those are questions that can sometimes feel like we might be opening up a Pandora’s box. And how will we ever get it closed? And, of course, my response to that is, don’t worry about it. In the medical setting, we have all kinds of ways that we shut patients down when we need to. And so if we have a conversation with the patient that goes beyond the assessment that we need to conduct or the evaluation that we need to make about safety, we have ways of steering our patients in the conversation back to important parts that we need to cover. So not to worry– we all have those skills. We might also have fears about not knowing what to do if someone tells us they’re at risk of self-harm. And this is an important fear that we need to tune into and also talk back to. So we know that risk of self-harm and harm to patients is part of our medical environment, in the sense that we have many different kinds of medical presentations that can represent threat to the health and safety of our patients, whether it is chest pain or whether it’s hypoglycemia or maybe it’s hyperglycemia and DKA, we have protocols for all of these different kinds of medical presentations of what to do, how to assess, how to evaluate, and steps to take, depending on the outcomes of those assessment questions. Suicidal ideation is the same. Every health care system has protocols for how to handle these situations. And so if we don’t happen to be familiar with those protocols, we know that we can turn to our practice protocols and use those steps to address these kinds of questions when they come up with our patients. And in that way, it is very much the same as what we would do for any other kind of medical presentation. We have tools, we have processes, and we have steps that we can take. And finally, I would say that there’s one other fear that sometimes we have tucked in the back of our brain that is really kind of a myth around self-harm and suicidal ideation, and that is that if we bring up the topic, if we ask people about thoughts of death or thoughts of self-harm or intent to engage in self-harm, are we inducing that idea for the very first time, and will that place our patient at greater risk simply by talking about it? The very good news is that it does not work that way. That if people are thinking about self-harm, they’re thinking about it long before we raise the question. And that, in fact, the idea of asking about self-harm can be a tremendous relief for people, because they may have been thinking about this in the deep recesses of their mind for a long time before they’re asked about it. And to get that out into the open and to have someone to talk with about it who will not be shaming or blaming, whose understanding, but who’s also in a position to take steps to help the patient be safe, can be a tremendous relief for people who are having those kinds of thoughts. So asking about it is very important. Because if it is there, it needs to be addressed. And if it’s not there, we have the relief of knowing that our patient is feeling safe and that we can proceed with the other aspects of the agenda that they bring to the table and that we want to address as well.

Provided by Medicine Matters diabetes; ©2021 Springer Healthcare Ltd, part of the Springer Nature Group.

De consequenties van opt-in of opt-out

jul 2023

Lees meer over De consequenties van opt-in of opt-out

Project tegen verspilling van dure medicijnen krijgt landelijk vervolg

jul 2023

Lees meer over Project tegen verspilling van dure medicijnen krijgt landelijk vervolg

‘Gezamenlijk echt anders gaan denken en werken’

jul 2023

Lees meer over ‘Gezamenlijk echt anders gaan denken en werken’

Hypoglykemie vermindert hersenfunctie

jun 2023 | Diabetes

Lees meer over Hypoglykemie vermindert hersenfunctie

Hersenen registreren bij obesitas onvoldoende dat er eten in maag zit

jun 2023

Lees meer over Hersenen registreren bij obesitas onvoldoende dat er eten in maag zit

Sluisplaatsing upadacitinib, pegunigalsidase alfa en niraparib-abirateron

mei 2023 | IBD, Uro-oncologie

Lees meer over Sluisplaatsing upadacitinib, pegunigalsidase alfa en niraparib-abirateron

EASD Highlights 2024

4 nov 2024 om 20:00 | Dementie, Diabetes

Lees meer over EASD Highlights 2024

ERA Highlights 2024

2 jul 2024 om 20:30 | Chronische nierschade, Dialyse

Lees meer over ERA Highlights 2024

Optimaal teamwork bij de DM2-patiënt met chronische nierschade

27 feb 2024 om 20:00 | Chronische nierschade, Diabetes

Lees meer over Optimaal teamwork bij de DM2-patiënt met chronische nierschade

ASN Highlights 2023

28 nov 2023 om 20:30 | Chronische nierschade, Diabetes

Lees meer over ASN Highlights 2023

EASD Highlights 2023

15 nov 2023 om 20:00 | Diabetes

Lees meer over EASD Highlights 2023

Keynote Webinar: Spotlight on Diet and Diabetes

8 nov 2023 om 18:00 | Diabetes

Lees meer over Keynote Webinar: Spotlight on Diet and Diabetes

ERA Highlights 2023

11 jul 2023 om 20:00 | Dialyse, Niertransplantatie

Lees meer over ERA Highlights 2023

'Wat is de toegevoegde waarde om ook het darmhormoon GIP te activeren?'

3 jul 2023 om 20:00 | Diabetes

Lees meer over 'Wat is de toegevoegde waarde om ook het darmhormoon GIP te activeren?'

Optimaal teamwork bij de DM2-patiënt met zeer hoog risico

30 mrt 2023 om 20:30 | Chronische nierschade, Diabetes, Hartfalen

Lees meer over Optimaal teamwork bij de DM2-patiënt met zeer hoog risico

Diabetestechnologie: het bespreken waard!

Diabetes

Lees meer over Diabetestechnologie: het bespreken waard!

Pedagogisch perspectief in de zorg voor jongeren met diabetes: de kracht van luisteren naar de stem van jongeren

Diabetes

Lees meer over Pedagogisch perspectief in de zorg voor jongeren met diabetes: de kracht van luisteren naar de stem van jongeren

NDF Nascholing – Preventieve voetzorg bij diabetes

Diabetes

Lees meer over NDF Nascholing – Preventieve voetzorg bij diabetes

Eerste hulp bij diabetisch voetulcus – een multidisciplinaire NDF nascholing

Diabetes

Lees meer over Eerste hulp bij diabetisch voetulcus – een multidisciplinaire NDF nascholing

Het Diabetes Jaargesprek; middel om zorg op maat bij diabetes te leveren

maandag 3 okt 2022 t/m dinsdag 1 jan 2030 | Diabetes

Lees meer over Het Diabetes Jaargesprek; middel om zorg op maat bij diabetes te leveren

Nationale Diabetes Dag 2024

vrijdag 8 nov 2024 van 09:00 tot 17:00 | Diabetes

Lees meer over Nationale Diabetes Dag 2024

Effect diabetesmedicatie op neuropsychiatrische stoornissen

sep 2024 | Dementie, Diabetes

Lees meer over Effect diabetesmedicatie op neuropsychiatrische stoornissen

Hogere Time In Tight Range, minder complicaties

sep 2024 | Diabetes

Lees meer over Hogere Time In Tight Range, minder complicaties

Directe vergelijking tirzepatide, liraglutide en semaglutide in netwerkmeta-analyse

sep 2024 | Diabetes

Lees meer over Directe vergelijking tirzepatide, liraglutide en semaglutide in netwerkmeta-analyse

Semaglutide ook effectief bij verminderde nierfunctie

sep 2024 | Diabetes

Lees meer over Semaglutide ook effectief bij verminderde nierfunctie

Wekelijks basaal insuline effectief bij type 1-diabetes

sep 2024 | Diabetes

Lees meer over Wekelijks basaal insuline effectief bij type 1-diabetes

Insulineresistentie gerelateerd aan 31 ziektes

sep 2024 | Bacteriële infecties, Bewegingsstoornissen, Diabetes, Jicht, Pancreatitis

Lees meer over Insulineresistentie gerelateerd aan 31 ziektes

AI-algoritme screent nauwkeurig op type 2-diabetes

sep 2024 | Diabetes

Lees meer over AI-algoritme screent nauwkeurig op type 2-diabetes

Semaglutide en tirzepatide effectief bij diabetes type-1

sep 2024 | Diabetes

Lees meer over Semaglutide en tirzepatide effectief bij diabetes type-1

Eerste nieruitkomststudie met semaglutide in zeerhoogrisicogroep

sep 2024 | Chronische nierschade, Diabetes

Lees meer over Eerste nieruitkomststudie met semaglutide in zeerhoogrisicogroep

ERA Highlights 2023 Podcast

aug 2023 | Dialyse, Niertransplantatie

Lees meer over ERA Highlights 2023 Podcast

De inzet van farmacotherapie bij obesitas: de aanpak in Canada

nov 2021

Lees meer over De inzet van farmacotherapie bij obesitas: de aanpak in Canada

Podcast: Christel Hendrieckx over de psychologische impact van hypoglykemie

okt 2020 | Diabetes

Lees meer over Podcast: Christel Hendrieckx over de psychologische impact van hypoglykemie

Podcast: William Polonsky over de impact van 'diabetes distress' op welzijn en glucoseregulatie

okt 2020 | Diabetes

Lees meer over Podcast: William Polonsky over de impact van 'diabetes distress' op welzijn en glucoseregulatie

Frank Snoek over de rol van de EASD-studiegroep Psychosocial Aspects of Diabetes

sep 2020 | Diabetes

Lees meer over Frank Snoek over de rol van de EASD-studiegroep Psychosocial Aspects of Diabetes

Neuropathische pijn bij diabetes

feb 2020 | Diabetes

Lees meer over Neuropathische pijn bij diabetes
Geen digitale kranten gevonden.